The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has been demonstrated to prolong the progression-free survival (PFS) of glioblastoma (GBM); however, patients still progress after 3–6 months with an OS of 6–9 months after salvage treatments [3]. Here, VEGFA is linked to glioblastoma.